IRCT20201128049515N1招募中2 期
The efficacy and safety of Silymarin in chemotherapy-induced peripheral neuropathy (CIPN): a randomized double-blind clinical trial study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of cancer
- •At least 18 years of age
- •Having chemotherapy-induced peripheral neuropathy (CIPN).
排除标准
- •Having a known disease predisposing to neuropathy, including diabetes, neuromuscular disease, vitamin B12 deficiency, amyloidosis, and connective tissue disease, a history of neurological diseases such as hereditary and acquired neuropathies
- •Unbearable side effects of the drug or drug reaction
- •Taking any antioxidant supplement in the last two months
- •Pregnancy, or breastfeeding
- •unwillingness to attend the study
研究者
相似试验
招募中
3 期
Silymarin in multiple SclerosisTherapeutic effect of silymarin.IRCT20171220037977N1Esfahan University of Medical Sciences60
尚未招募
2 期
Silymarin capsule in COVID-19COVID-19 disease.COVID-19U07.1IRCT20180103038199N10Mashhad University of Medical Sciences140
已完成
3 期
The effect of silymarin on methadone poisoningIRCT20210216050377N1Shahre-kord University of Medical Sciences64
尚未招募
3 期
Effect of silymarin in inflammatory bowel diseaseK50-K52Inflammatory Bowel Disease.Noninfective inflammatory bowel diseaseIRCT20101107005123N3Mashhad University of Medical Sciences40
已完成
2 期
To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesionsIRCT20150905023897N5Vice chancellor for research Tarbiat Modares University60